J&J's Bid For Crucell Hits Speed Bump With Shipment Suspension At Korean Vaccine Plant

Johnson & Johnson's acquisition offer for Crucell appears to be on track despite news that the Dutch biotech firm suspended all shipments of hepatitis B vaccine Hepavax-Gene and childhood pediatric vaccine Quinvaxem due to issues at its Korean unit Berna Biotech Korea.